Treatments

*February 2024* Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor that holds substantial importance in understanding the disease progression and guiding treatment strategies. Tumor cells acquire somatic mutations in both oncogenes and tumor suppressor genes (TSGs) leading to tumorigenesis.1  The event of multiple mutations emerging…

*March 2024* The FDA has approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.1,2 The regulatory agency also granted full approval to amivantamab in adult patients…

*January 2024* This recorded webinar is an update on research supported by our joint grant! Hear from 2022 grant recipients Dr. Swarnali Acharyya, Dr. Luke Hoeppner, and Dr. Jonathan Ostrem.LCRF.  Watch here.

*January 2024* Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. Listen to the podcast or read the transcript here.

*January 2024* In Part One of a two-part podcast on oligometastatic lung cancer, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as radiation, cryoablation, and surgery, impact the treatment of this complex form of lung cancer. In Part Two of this Lung Cancer Considered podcast…

*January 2024* Note: This article discusses the analysis of circulating tumor DNA (ctDNA) in the context of osimertinib treatment for non-small cell lung cancer (NSCLC), specifically focusing on resistance mechanisms. It highlights the complexity of resistance mechanisms associated with osimertinib treatment in NSCLC and the importance of understanding genetic changes for effective management.…

*January 2024* A premarket approval (PMA) application regarding the addition of tumor-treating fields (TTFields) to standard-of-care (SOC) therapies in patients with non­–small cell lung cancer (NSCLC) after disease progression on or following platinum-based treatment has been accepted for filing by the FDA.1 The PMA was supported by data from the phase…

*January 2024* Treatment with patritumab deruxtecan (HER3-DXd) in patients with locally advanced or metastatic, EGFR-mutated non–small cell lung cancer (NSCLC) resulted in clinically meaningful efficacy and long-lasting responses in those who progressed following EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy, according to data from the phase 2 HERTHENA-Lung01 study…

*January 2024* While the standard-of-care recommendations can vary depending on the individual patient, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib (Tagrisso) have played a pivotal role in the treatment of patients with EGFR-mutated lung cancer in recent years. Osimertinib tends to be the preferred first-line treatment for most patients who harbor…

*December 2023* Introduction NSCLC transformation to SCLC has been best characterized with EGFR-mutant NSCLC, with emerging case reports seen in ALK, RET, and KRAS-altered NSCLC. Previous reports showed transformed SCLC from EGFR-mutant NSCLC portends very poor prognosis and lack effective treatment. Genomic analyses showed TP53 and RB1 loss of function increase the risk of SCLC transformation. Little has been…